Hugel Aesthetics

What Hugel Aesthetics does

Hugel Aesthetics operates as the U.S. commercial subsidiary (Hugel America, Inc.) of KOSDAQ-listed parent Hugel Inc., a Seoul-founded (2001) biopharmaceutical company specializing in injectable aesthetic products. The subsidiary, headquartered at 1200 Newport Center Drive in Newport Beach, California, markets and distributes the "Triangle Formation" portfolio of botulinum toxin type A (Letybo / letibotulinumtoxinA-wlbg), hyaluronic acid dermal fillers (Chaeum), and bio-cosmetics (WELLAGE, BYRYZN BR, OPULUXE V) to licensed medical aesthetic professionals — physicians, dermatologists, plastic surgeons, and medical spas.

The company's core technology is built around 25 years of focused R&D in botulinum toxin formulation, anchored by Letybo, which became the first South Korean botulinum toxin type A approved simultaneously by the U.S. FDA (2024), China's NMPA (2020), and the EU (2022). Letybo is approved for the temporary improvement of moderate to severe glabellar lines and has held the #1 neurotoxin brand position in South Korea by revenue from 2016 through 2025. Cumulative production exceeds 44 million vials globally as of May 2026, with distribution authorized across more than 70 countries spanning the Americas, Europe, and Asia-Pacific. The portfolio is positioned as a comprehensive K-aesthetics offering, with plans to enter the ECM-based injectable market in 2026.

Revenue is generated through prescription product sales to healthcare professionals via a hybrid model combining enterprise field sales, the Hugel Hub professional portal for direct order management, and authorized distributor networks in international markets. The company is led by Carrie Strom (President & Global CEO since October 2025; previously Global President of Allergan Aesthetics), with a U.S. leadership bench drawn largely from Allergan, AbbVie, Evolus, Revance, and Azura Ophthalmics. Marketing leverages earned media (Vogue, Allure, Elle, Harper's Bazaar), industry events such as AMWC Korea, a celebrity endorsement by actor Ji Chang-wook, and social channels on Instagram and LinkedIn to drive both consumer awareness and practitioner pull-through.

Name

Hugel Aesthetics

Legal name

Hugel America, Inc.

Website

https://hugel-aesthetics.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Hugel Aesthetics is the U.S. subsidiary of Seoul-based Hugel Inc., marketing FDA-approved botulinum toxin (Letybo), HA dermal fillers (Chaeum), and K-beauty cosmeceuticals to licensed medical aesthetic professionals in the United States and across 70+ countries.

Ownership category

akta.pro rank

Product category

Medical Aesthetics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Aesthetic medical products
• Botulinum toxin injections
• Dermal fillers
• Medical aesthetics
• K-beauty neurotoxins

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Aesthetic Medical Products: Revenue is generated through the sale of prescription aesthetic medical products to healthcare professionals and clinics. The portfolio includes neurotoxins (Letybo), hyaluronic acid fillers (Chaeum), skin boosters, threads, and cosmeceuticals (BYRYZN, OPULUXE V, WELLAGE). Products are sold through a combination of direct sales relationships managed via Hugel Hub and distributor networks across 70+ countries.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Hugel Aesthetics develops, manufactures, and sells prescription aesthetic medical products to licensed medical professionals, including botulinum toxin type A neurotoxin (Letybo), hyaluronic acid dermal fillers (Chaeum), skin boosters, threads, and bio-cosmetics/skincare (WELLAGE, BYRYZN BR, OPULUXE V). The portfolio is marketed as the 'World's First Triangle Formation' aesthetic offering combining neurotoxins, fillers, and cosmeceuticals. Products are distributed across 70+ countries primarily through a B2B professional sales motion.

Product overview

Hugel Aesthetics operates as a comprehensive K-Aesthetics portfolio company offering botulinum toxin (Letybo - FDA-approved neurotoxin), hyaluronic acid fillers (Chaeum), skin boosters, threads, and bio-cosmetics (WELLAGE, BYRYZN BR, OPULUXE V). The company distributes across 70+ countries and serves professionals through the Hugel Hub platform for order management and relationship support. Founded in Seoul in 2001, Hugel evolved from a single-focus botulinum toxin company to a full-spectrum aesthetic solutions provider known as the "World's First Triangle Formation."

Differentiator

Problem solved

Functional benefit

Brands

• Letybo: FDA-approved botulinum toxin neurotoxin product; Korea's #1 neurotoxin brand.
• BYRYZN BR
• OPULUXE V
• WELLAGE
• The Chaeum
• Hugel Hub

Products and services

• Letybo (letibotulinumtoxinA-wlbg) FDA-approved botulinum toxin type A neurotoxin injectable for the temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. Korea's #1 neurotoxin brand by total reported revenue 2016-2025. Prescription-only for qualified medical professionals.
• Chaeum Hyaluronic acid (HA) dermal filler for facial aesthetic injectable treatments, approved by Korea FDA in 2014 and part of Hugel's HA filler portfolio.
• WELLAGE Bio-cosmetics skincare brand offering aesthetic skincare solutions; top-selling skincare brand in Korea's Olive Young.
• BYRYZN BR Cosmeceutical product in Hugel's portfolio for aesthetic skin enhancement applications.
• OPULUXE V Cosmeceutical product (Byryzn 3.3 mL vial format) in Hugel's advanced skincare line.
• Hugel Hub Centralized professional portal enabling authorized medical aesthetic customers to place orders, view order history, and download marketing resources for Hugel Aesthetics products.

Quantifiable outcome

• 44M+ toxin vials sold globally as of May 2026
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• L'Oréalnotable industry developmentOthersIn August 2024, L'Oréal acquired a 10% stake in Switzerland-based Galderma Group AG for $1.85 billion, forming a strategic partnership to combine Galderma's dermatology expertise with L'Oréal's skin biology and diagnostic technologies. Galderma is identified as a key market player in the botulinum toxins market alongside Hugel.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AbbVie (Allergan Aesthetics): Owns BOTOX and BOTOX Cosmetic, the dominant neurotoxin in the US aesthetic market. Direct competitor in injectable aesthetics with the same core product category and prescriber customer base as Hugel's Letybo.
• Evolus: US aesthetics company commercializing Jeuveau (prabotulinumtoxinA-xvfs), a competing neurotoxin positioned as a value alternative to BOTOX. Several Hugel US executives (Agarwal, Gores, Newnam) came directly from Evolus, making it a near-twin peer for both product and talent competition.
• Galderma: Global dermatology-focused aesthetics company offering Dysport/Azzalure (botulinum toxin) along with fillers and skincare. Identified in market research as a direct head-to-head competitor alongside Hugel in the global BTx market.
• Revance Therapeutics: Develops and markets DAXXIFY, a longer-duration botulinum toxin, plus the RHA filler collection. Competes in both neurotoxin and filler categories where Hugel plans to expand. Newnam previously held senior legal roles at Revance.
• Merz Pharma: Privately held German specialty pharma offering Xeomin (incobotulinumtoxinA) in the neurotoxin market plus the Belotero filler line and Ultherapy. Direct multi-product aesthetic competitor across both toxin and filler segments.
• Ipsen: Global pharmaceutical company that commercializes Dysport in many ex-US markets through partnership with Galderma. Identified in market research as one of four key global BTx players alongside Hugel.

Emerging players

• Medytox: South Korean biopharmaceutical company developing competing botulinum toxin products (Meditoxin/Relatox). Represents the Korean biosimilar pricing pressure cited in market research as a competitive threat to Hugel's Korean-origin premium positioning.
• Daewoong Pharmaceutical: South Korean pharma company with Nabota, a botulinum toxin approved in multiple global markets. Competes directly with Hugel in Korea and is among the Korean biosimilar producers identified as price-disruptive in the global market.
• Sinclair Pharma: European aesthetics company offering HA fillers, biostimulators (Ellansé), and PDO threads. Indirect competitor in Hugel's planned filler and skin booster expansion segments, particularly outside the US.
• Croma-Pharma: Austrian aesthetics company specializing in HA fillers, skin boosters, and PDO threads. Recently partnered with Hugel per the company description to develop a synergistic aesthetic portfolio combining HA fillers and botulinum toxin.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hugelaesthetics
• Instagraminstagram.com/hugel_aesthetics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hugel Aesthetics